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36Background:Molecular testing of patients with advanced non–small cell lung cancer for personalized therapy
often is limited by insufficient specimen from nonsurgical biopsies. We measured the feasibility, patient safety,
and clinical impact of thoracic surgical tumor biopsy in patients with stage IV non–small cell lung cancer.
Methods: This is a single institution retrospective analysis. Patients with stage IV non–small cell lung cancer
undergoing elective surgical tissue biopsy for molecular analysis were evaluated fromMarch 2011 to November
2012. Perioperative specific variables were measured.
Results: Twenty-five patients with known or suspected stage IV non–small cell lung cancer undergoing surgical
biopsy were identified. All cases were discussed at a multidisciplinary thoracic oncology conference or a multi-
disciplinary thoracic oncology clinic. Preoperative histologies included adenocarcinoma in 20 patients (80.0%)
and squamous cell carcinoma in 2 patients (8.0%). Surgical procedures consisted of video-assisted thoracic
surgery wedge biopsy (16, 64%), video-assisted thoracic surgery pleural biopsy (4, 16.0%), mediastinoscopy
(2, 8.0%), supraclavicular/cervical lymph node excisional biopsy (3, 12.0%), and rib/chest wall resection
(2, 8.0%). There were no deaths and 5 postoperative complications (20.0%). Surgery identified potentially
targetable molecular information in 19 of the total patients undergoing operation (76.0%) and changed the
treatment strategy in 14 patients (56.0%); 10 of the total cohort (40.0%) were enrolled into therapeutic targeted
clinical trials.
Conclusions: These data suggest that thoracic surgical biopsy can be safely performed in appropriately selected
patients with stage IV non–small cell lung cancer and direct personalized therapy and enrollment into relevant
clinical trials. Patients with advanced-stage non–small cell lung cancer should be discussed in a multidisci-
plinary setting to determine the need and strategy for thoracic surgical biopsy for molecular analysis. (J Thorac
Cardiovasc Surg 2014;148:36-40)Seventy percent of patients with non–small cell lung cancer
(NSCLC) present with stage IV disease.1 Molecular testing
for targeted personalized therapy has led to progress in
treating patients with NSCLC. Clinically validated
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The Journal of Thoracic and Cardiovascular Surgereceptor (EGFR) sensitizing mutations, echinoderm
microtubule-associated protein-like 4 and anaplastic
lymphoma kinase (EML4-ALK) fusion oncogene, and
excision repair cross-complementing rodent repair
deficiency, complementation group 1 expression.2-4 The
clinical success of targeted therapy based on a lung
cancer’s molecular and genomic profile has led to clinical
guidelines advocating the routine testing for EGFR
mutation and EML4-ALK fusion oncogene at the time of
diagnosis for all patients presenting with stage IV disease
or recurrence or progression in patients who may have
originally presented with lower-stage disease but do not
have genomic information.5
These and other biomarkers require significant tissue to
achieve an accurate molecular profile, and for most
genomic analysis, at least 200 to 400 malignant cells are
needed to develop successful information.6 Because the
majority of patients with NSCLC present with advanced
disease, diagnosis often is made with small fine-needle
aspiration or core needle biopsies. In the initial presentation
of stage IV NSCLC, tissue acquisition has the dual goal
of histologic diagnosis and molecular tumor profiling,
and computed tomography (CT)-guided percutaneous andry c July 2014
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
EGFR ¼ epidermal growth factor receptor
EML4-ALK ¼ echinoderm microtubule-associated
protein-like 4 and anaplastic
lymphoma kinase
NSCLC ¼ non–small cell lung cancer
PLOS ¼ prolonged length of stay
RRM1 ¼ ribonucleoside-diphosphate
reductase large subunit
TKI ¼ tyrosine kinase inhibitor
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Sendobronchial strategies (eg, endobronchial ultrasound-
transbronchial needle aspiration) offer excellent results,
demonstrating success in providing adequate tumor
specimen for molecular analysis in 80% to 90% of patients.
However, endobronchial biopsy specimen results in a mean
percentage area of tumor of 33%, with less than half of
endobronchial biopsy specimen containing tumor, and
CT-guided core specimen may be inadequate in 10% of
specimen after 4 to 5 passes.7,8
As a result of the variability of success of percutaneous or
natural orifice biopsy of NSCLC for molecular profiling,
thoracic surgeons are frequently requested to perform
minimally invasive surgical biopsies in patients with stage
IV disease. Thoracic surgical procedures in patients with
advanced-stage NSCLC, even if performed minimally inva-
sively,might be high riskwith an elevated complication rate.
The aimsof our studywere to (1)measure the feasibility and
patient safetyof thoracic surgical tumorbiopsy inpatientswith
metastatic (stage IV) NSCLC for molecular testing and (2)
determine the impact of thoracic surgical biopsy formolecular
testing on subsequent therapeutic decision-making.
PATIENTS AND METHODS
This is a single institution descriptive, retrospective analysis. Patients with
suspected stage IV NSCLC undergoing elective surgical tissue biopsy for
molecular analysis were evaluated from March 2011 to November 2012. All
thoracic surgical biopsieswere performed in the operating roomusing general
anesthetic. The cases were prospectively discussed at a multidisciplinary
thoracic oncology conference or a multidisciplinary thoracic oncology clinic.
Discussions achievedconsensus agreement on the likelihoodof successof new
or additional percutaneous or endobronchial biopsy, the appropriateness and
best targets for surgical biopsy, the timing of operation in the day to best
coordinate optimal tissue transport, and what analytic tests will be performed.
Patient, tumor, and postoperative outcome specific variables were measured.
The institutional review board of the University of California, Davis Medical
Center, approved the study of these patient cohorts.
Patient and Hospital Demographics and
Perioperative Outcomes
Patient demographics studied included age, sex, race, performance
status as defined by Zubrod performance status score (score 1-5), andThe Journal of Thoracic and CAmerican Society of Anesthesiologists physical status classification system
class (class 1-6). Tumor-specific variables included histology, preoperative
(if any) and postoperative molecular profile, and reason for surgical biopsy
(ie, disease progression, better define histology, second opinion for a
clinical trial). Perioperative outcomes measured included type of thoracic
surgical procedure, postoperative complications, length of hospital stay in
days, occurrence of prolonged length of stay (PLOS) as defined by hospital
staymore than 14 days, discharge disposition (routine to home, institutional
care facility, or death at the time of discharge), same-stay reoperations,
30-day hospital readmissions, and 30-day revisits defined by emergency
department visits, unplanned clinic visits, or telephone encounters requiring
clinical intervention, all not resulting in a hospital readmission.
Molecular Tumor Analysis
The molecular profile of tumor surgical samples from patients with
confirmed NSCLC were analyzed by Response Genetics Inc (Los Angeles,
Calif). Molecular information included EGFR activating mutations
(exon-19 deletion, L858R and L861Q) and resistance mutations (T790M),
EML4-ALK fusion, V-Ko-ras2 Kirsten rat sarcoma viral oncogene homolog
mutations (Gly12Arg mutation), EGFR overexpression, excision repair
cross-complementing rodent repair deficiency, complementation group 1
expression, ribonucleoside-diphosphate reductase large subunit expression,
and Met proto-oncogene expression. Patient encounters were reviewed for
change in medical oncology management or enrollment in a therapeutic
targeted clinical trial on the basis of the thoracic surgical biopsy results.
Statistical Analysis
All analyses and descriptive and binomial confidence limits as
proportions (95% confidence interval [CI]) were performed using
Microsoft Excel Version 14.1.0 (Microsoft Corp, Redmond, Wash).
RESULTS
Patient Demographics
Twenty-five patients with known or suspected stage IV
NSCLC undergoing surgical biopsy were identified
(Table 1). Mean age was 55.8 years (range, 36-79 years),
and mean Zubrod performance status was 1.2. Zubrod per-
formance status was 0 in 2 patients, 1 in 16 patients, 2 in 5
patients, and 3 in 1 patient. Fourteen (56%) of the patients
were female, and themajority of patients were of white race.
Tumor Characteristics
Preoperative histologies (Table 1) were adenocarcinoma
(20, 80.0%), squamous cell carcinoma (2, 8.0%), neuroen-
docrine (1, 4.0%), and unknown (2, 8.0%). The 2 unknown
histologies were suspected to be stage IV NSCLC tumors,
but proved to be mesothelioma and angiosarcoma after
thoracic surgical biopsy. Eight patients had undergone
nonsurgical biopsy for molecular testing but had insuffi-
cient tissue (7 image guided and 1 endobronchial ultrasound
guided). Eleven patients had preoperative molecular data.
Four of the 7 patients with known tumors with preoperative
EGFR-sensitizing mutations were found to have new EGFR
resistance mutations after thoracic surgical biopsy. Two of
the 3 patients who had a negative molecular target analysis
of their tumors preoperatively were found to havemolecular
targets after thoracic surgical biopsy. The majority of
patients underwent thoracic surgical biopsy for molecularardiovascular Surgery c Volume 148, Number 1 37
TABLE 1. Patient and tumor characteristics
Characteristic Result
Age Mean 55.8 y, median 56 (range, 36-79) y
Zubrod score Mean 1.2, median 1.0 (range, 0-3)
ASA physical status
classification system
Mean 2.8, median 3 (range, 1-4)
Characteristic N (%)
Sex
Male 14 (56.0)
Female 11 (44.0)
Race
White 19 (76.0)
Black 1 (4.0)
Asian/Pacific Islander 4 (16.0)
Hispanic/Latino 1 (4.0)
Preoperative histology
Adenocarcinoma 20 (80)
Squamous cell 2 (8.0)
Neuroendocrine 1 (4.0)
Unknown 2 (8.0)
Preoperative molecular target data (yes) 11 (44.0)
EGFR-sensitizing mutations 7 (28.0)
EGFR resistance mutations 0
EML4-ALK fusion 1 (4.0)
No molecular target identified 3 (12.0)
Clinical impetus for procedure
Disease progression after frontline therapy 21 (84.0)
Define histology 2 (8.0)
Second opinion for clinical trial 2 (8.0)
ASA, American Society of Anesthesiologists; EGFR, epidermal growth factor recep-
tor; EML4-ALK, echinoderm microtubule-associated protein-like 4 and anaplastic
lymphoma kinase.
TABLE 2. Perioperative characteristics
Characteristic N (%)
Surgical procedure
VATS lung biopsy 16 (64.0)
VATS pleural biopsy 4 (16.0)
Mediastinoscopy 2 (8.0)
Chest wall biopsy/rib resection 2 (8.0)
Supraclavicular/cervical lymph node biopsy 3 (12.0)
Discharge
Home 25 (100)
ICF 0
Death 0
Complications (minor) 3 (12.0)
Wound infections 2 (8.0)
Urinary tract infections 1 (4.0)
Complications (major) 2 (8.0)
Hemothorax 1 (4.0)
ICU admission 1 (4.0)
Length of stay, in days Median 1 (range, 0-4)
PLOS 0
Same-stay reoperations 1 (4.0)
30-d readmissions 1 (4.0)
30-d revisits 3 (12.0)
ICF, Institutional care facility; ICU, intensive care unit; PLOS, prolonged length of
stay (>14 days); VATS, video-assisted thoracic surgery.
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apy (21, 84%).Perioperative Results
Surgical procedures (Table 2) consisted of video-assisted
thoracic surgery wedge biopsy (16, 64%), video-assisted
thoracic surgery pleural biopsy (4, 16.0%), mediastino-
scopy (2, 8.0%), supraclavicular/cervical lymph node exci-
sional biopsy (3, 12.0%), and rib/chest wall resection
(2, 8.0%). Review of postoperative outcomes demonstrated
no deaths (0%; 95% CI, 0-13.7), and all patients were dis-
charged to home. There were 3 minor postoperative compli-
cations (12.0%), consisting of 2 wound infections and 1
urinary tract infection. There were 2 major complications
(8%) consisting of 1 hemothorax requiring the only
same-stay reoperation and 1 unplanned intensive care unit
admission. A total of 5 patients had complications (20%;
95% CI, 6.8-40.7). The median length of stay was 1 day
(range, 0-4 days), with no incidence of PLOS. There was
one 30-day readmission for a partial small-bowel obstruc-
tion unrelated to the thoracic surgical biopsy. There were
three 30-day revisits; 2 telephone encounters requiring38 The Journal of Thoracic and Cardiovascular Surgeclinical intervention (1 surgical wound infection and 1 un-
related port-a-catheter site infection) and 1 emergency
department visit for a chronic obstructive pulmonary dis-
ease exacerbation.
Surgical biopsy led to the identification of potentially
targetable molecular information in 19 of the total patients
undergoing operation (76.0%; Table 3). Surgical biopsy
was diagnostic in all but 1 patient (96.0%). Surgical data
changed the treatment strategy for 14 patients (56.0%),
and 10 of those patients (71.4%; 40.0% of total cohort)
were enrolled into therapeutic targeted clinical trials on
the basis of surgical pathology results. Of the 11 patients
who had preoperative molecular data, surgical biopsy
changed the treatment strategy in 5 patients (45.5%),
although this resulted in only 2 of those patients to be
enrolled into targeted therapeutic clinical trials (18.2%).DISCUSSION
This study demonstrated that elective thoracic surgical
biopsy in patients with stage IVNSCLC for the specific pur-
pose of molecular testing is feasible and safe, offering a low
morbidity and mortality. In addition, thoracic surgical bi-
opsy changed the subsequent treatment strategy in the ma-
jority of patients and allowed 40% of patients to be enrolled
into targeted therapeutic clinical trials.
The success of targeted therapy based on the molecular
tumor profile in advanced NSCLC has increased the de-
mand for abundant representative tissue. Especially in the
setting when diagnostic percutaneous or natural orificery c July 2014
TABLE 3. Molecular targets identified
Description N
Patient tumors
confirmed tested
for this target %
Principle lung cancer molecular targets
EGFR-sensitizing mutations 10 22 45.5
EGFR resistance mutations 5 21 23.8
EML4-ALK fusion 2 21 9.5
KRAS mutations 2 21 9.5
Secondary lung cancer molecular targets
EGFR overexpression 7 21 33.3
ERCC1 low expression 9 21 42.9
RRM1 low expression 2 20 10.0
c-MET overexpression 7 19 36.8
c-MET, Met proto-oncogene; EGFR, epidermal growth factor receptor; EML4-ALK,
echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase;
ERCC1, excision repair cross-complementing rodent repair deficiency, complemen-
tation group 1; KRAS, V-Ko-ras2 Kirsten rat sarcoma viral oncogene homolog;
RRM1, ribonucleoside-diphosphate reductase large subunit.
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or the original tissue for patients who present with disease
progression or recurrence is unavailable, thoracic surgeons
are increasingly asked to perform minimally invasive surgi-
cal procedures to acquire tissue for molecular analysis.
Conventional wisdom would suggest that patients with
stage IV NSCLC would pose an at-risk population who
could make thoracic surgical biopsy for molecular profiling
relatively prohibitive. However, a review of our results dem-
onstrates a postoperative complication rate similar to and a
postoperative mortality rate superior to elective surgical
lung biopsy for interstitial lung disease.9,10
In the current environment of patient-centered quality,
the determinants of a successful surgical diagnostic and
treatment strategy go beyond the simple measurement of
postoperative complications and mortality. Discharge to
institutional care facilities, PLOS, 30-day readmissions,
and same-stay reoperations are all important metrics that
measure the effects of a procedure on the quality of life of
patients and potential strain on the healthcare system.11,12
In our study, thoracic surgical biopsy, for molecular
testing, was complicated only by an isolated 30-day read-
mission and same-stay reoperation, and no discharges to
institutional care facility or incidence of PLOS. In addition,
we sought to identify increased healthcare resource use that
would not be captured by measuring hospital readmissions,
defining the ‘‘30-day revisit,’’ or unplanned postdischarge
encounters requiring clinical intervention but not resulting
in a readmission. The 30-day revisit rate in our study group
was 12%. Although this result seems low, the 30-day revisit
rate is a new, not yet validated metric, and therefore it is un-
clear whether a 12% rate is a satisfactory result.
In the examined cohort, thoracic surgical biopsy influ-
enced the patient management. Four of the 7 patients with
known tumors with preoperative EGFR-sensitizingThe Journal of Thoracic and Cmutations were found to have new EGFR resistance muta-
tions after thoracic surgical biopsy. Identification of patients
with EGFR resistance mutations can change the treatment
strategy from first-generation EGFR tyrosine kinase inhib-
itors (TKIs) to second- or third-generation novel EGFR
TKIs.13 Specifically, surgical data changed the treatment
strategy in 56% of the patients, with 40% of the total cohort
being enrolled into therapeutic targeted clinical trials on the
basis of surgical pathology results. This result is important
for the support of clinical trials for the advancement of
knowledge of the optimal treatment of lung cancer, but
there is evidence from the California Cancer Registry,
queried by Chow and colleagues,14 that patients with lung
cancer who participate in clinical cancer trials have a sur-
vival benefit. In addition, patients with advanced NSCLC
with EGFR mutant and ALKþ tumors have longer survival
compared with those who do not have these genetic abnor-
malities. These patients respond well to both EGFR TKIs
and the ALK targeting drug crizotinib and chemotherapy.
Improvement in overall survival has been difficult to
demonstrate because survival is confounded by cohort
crossover and the availability of many other active lines
of therapy, because these patients receive not only targeted
therapy but also multiple lines of chemotherapy. First-line
trials of targeted agents do not have survival benefit over
chemotherapy (except for tumor response rate and
progression-free survival), but second-line and beyond tri-
als have exhibited survival benefit.3,15,16
Study Limitations
Limitations of this study include the small cohort size and
the retrospective nature. The limitation of the small sample
size is reflective in the wide 95% CIs for mortality and
complication rates. All patients were discussed in a multi-
disciplinary stetting. The patients selected for thoracic sur-
gical biopsies were reviewed for the extent of their disease,
current availability of analyzable tissue, appropriateness for
percutaneous or endobronchial biopsy, and potential avail-
able clinical trial. In addition, the patients selected for bi-
opsy exhibited relatively preserved performance status
(mean Zubrod and American Society of Anesthesiologists
scores of 1.2 and 2.8, respectively), which would suggest
favorable clinical postoperative outcomes. One of the pa-
tients in the study had a Zubrod score of 3. The reason to
biopsy patients with NSCLC with a Zubrod score of 3 is
to determine whether the cancer is oncogene-driven
(EGFR or ALK). Although chemotherapy is not recommen-
ded for patients with a Zubrod performance status of 3 or
greater, treatment with TKIs is recommended.17
CONCLUSIONS
Although CT-guided percutaneous or endobronchial bi-
opsy should be considered the frontline approach for tissue
acquisition for molecular profiling in patients with stage IVardiovascular Surgery c Volume 148, Number 1 39
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SNSCLC, this study suggests that thoracic surgical biopsy
for molecular tumor analysis can be feasibly, safely, and
successfully performed in appropriately selected patients
and should be in the resource armamentarium for the multi-
disciplinary care of these challenging patients. Surgical
biopsy provides valuable pathologic and molecular infor-
mation that can direct appropriate personalized therapy
and serves to foster enrollment into relevant clinical trials.
Patients with advanced-stage NSCLC should be discussed
in a multidisciplinary setting to determine the need and
strategy for thoracic surgical biopsy for molecular analysis.
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